 AVROBIO, Inc. Nasdaq: AVRO and Magenta Therapeutics Nasdaq: MGTA today announced a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magentas novel targeted antibody-drug conjugate ADC for conditioning patients before they receive one of AVROBIOs investigational lentiviral gene therapies. 